To maximize the drugability potential, we target approaches to improve clinical benefits based on reverse translational science and emerging biology of the tumor microenvironment.
(Reverse)Translational Science
Identification of patients' unmet needs, novel targets, pathways, and mechanisms.
Drug Discovery & Development
Validation of target, mechanism of action, and proof of concept, and development of novel engager with high potency and good safety profile.
Immunotherapy
Boosting of anti-tumor immunity to fight against cancer.
Direct engagement of myeloid cells with target cells.
Activation of killing mechanism (such as phagocytosis) by myeloid cells directed towards target cells.
Stimulation of myeloid cells to release minimal cytokines and chemokines known to reprogram and reset the immunosuppressive tumor microenvironment and enhance cytotoxic T cell function.
Cross presentation of tumor neoantigens and activation of tumor-specific T cells to support durable anti-tumor immune responses and immunological memory.
REDWOOD CITY, Calif. & SHENZHEN, China – February 24, 2025 – LTZ Therapeutics, an immunotherapy-focused biotech company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for LTZ-301, a first-in-class myeloid engager immunotherapy intended to treat relapsed or refractory non-Hodgkin lymphoma (r/r NHL).
General Inquiries
info@ltztherapeutics.comBusiness Development
vivian.tian@ltztherapeutics.comRedwood City, USA
1100 Island Dr., Suite 103, Redwood City, CA, 94065Shenzhen, China
Room 209, Scientific Research Building, Tsinghua Hi-Tech Park, Nanshan District, Shenzhen, 518057@ 2025 LTZ Therapeutics Inc., All Rights Reserved.
Privacy Policy | Term of Use | Contact Us
为了更好的呈现效果，移动端请竖屏浏览
